Evaluating the Benefits and Drawbacks of Momelotinib for Treatment-Naïve Myelofibrosis Patients
-
By
-
Naseema Gangat
-
Ayalew Tefferi
-
May 7, 2025
Original Source(s)
Momelotinib in JAK2 inhibitor-naïve myelofibrosis: pros and cons
-
by Naseema Gangat, Ayalew Tefferi
May 7, 2025
Related Content
Clinical Reasoning in Practice: Implementing High-Value Care When Data Discrepancies Arise
by Rohan Rao, Katya Lavine, Anand A. Patel, Christopher Moriates
April 20, 2026
